Literature DB >> 19829123

Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease.

Murat Akyildiz1, Fulya Gunsar, Deniz Nart, Osman Sahin, Funda Yilmaz, Sinan Akay, Galip Ersoz, Zeki Karasu, Tankut Ilter, Yucel Batur, Afig Berdeli, Ulus Akarca.   

Abstract

AIM: To investigate the macrophage migration inhibitory factor (MIF) expression and -173 G/C polymorphism of the MIF gene in nonalcoholic fatty liver disease (NAFLD).
METHOD: Ninety-one patients with diagnosis of NAFLD and 104 healthy controls were included in the study. MIF -173 G/C polymorphism was detected using the PCR-restriction fragment length polymorphism based method. NAFLD was stratified as nonalcoholic steatohepatitis (NASH), probable NASH and steatosis, respectively in groups 1, 2 and 3, according to NAFLD Activity Score. MIF expression was detected by immunohistochemistry staining.
RESULTS: Mean age of the patients was 50.1+/-9.6 years, and 54 of them were male. Serum alanine aminotransferase and aspartate aminotransferase were 50/83, 42/63 and 31/32, respectively in groups 1, 2 and 3, (P<0.05). Both the MIF expression of hepatocytes and mononuclear cells were more prominent in groups 1 and 2 than group 3. There was no correlation between MIF expression of hepatocytes and fibrosis stage. However, MIF expression of mononuclear cells significantly increased according to fibrosis stage (P<0.05, R : 0.2). There was no significant correlation between MIF genotype and MIF expression in the liver.
CONCLUSION: MIF expression is significantly increased especially by mononuclear cells in liver tissue of patients with NASH secondary to inflammation. Thus, it should be considered as a consequence not a causal factor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19829123     DOI: 10.1097/MEG.0b013e328331a596

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  13 in total

1.  Macrophage migration inhibitory factor is required for recruitment of scar-associated macrophages during liver fibrosis.

Authors:  Mark A Barnes; Megan R McMullen; Sanjoy Roychowdhury; Nabil Z Madhun; Kathryn Niese; Mitchell A Olman; Abram B Stavitsky; Richard Bucala; Laura E Nagy
Journal:  J Leukoc Biol       Date:  2014-11-14       Impact factor: 4.962

2.  Macrophage migration inhibitory factor gene polymorphisms and plasma levels in children with obstructive sleep apnea.

Authors:  Abdelnaby Khalyfa; Leila Kheirandish-Gozal; Oscar Sans Capdevila; Rakesh Bhattacharjee; David Gozal
Journal:  Pediatr Pulmonol       Date:  2012-03-26

3.  Swimming prevents nonalcoholic fatty liver disease by reducing migration inhibitory factor through Akt suppression and autophagy activation.

Authors:  Haiying Tang; Xiaoyan Tan; Lei Zhu; Kairong Qin; Huan Gao; Hao Bai
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

Review 4.  Identifying Novel Targets for Treatment of Liver Fibrosis: What Can We Learn from Injured Tissues which Heal Without a Scar?

Authors:  Michele T Pritchard; Jennifer M McCracken
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

5.  Macrophage migration inhibitory factor contributes to ethanol-induced liver injury by mediating cell injury, steatohepatitis, and steatosis.

Authors:  Mark A Barnes; Megan R McMullen; Sanjoy Roychowdhury; Sorana G Pisano; Xiuli Liu; Abram B Stavitsky; Richard Bucala; Laura E Nagy
Journal:  Hepatology       Date:  2013-01-18       Impact factor: 17.425

Review 6.  Role of Macrophage Migration Inhibitory Factor in Obesity, Insulin Resistance, Type 2 Diabetes, and Associated Hepatic Co-Morbidities: A Comprehensive Review of Human and Rodent Studies.

Authors:  Martine C Morrison; Robert Kleemann
Journal:  Front Immunol       Date:  2015-06-15       Impact factor: 7.561

7.  Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease.

Authors:  Kayleigh L Wood; Michael H Miller; John F Dillon
Journal:  BMJ Open Gastroenterol       Date:  2015-02-17

Review 8.  Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease.

Authors:  Eugene Chang; Cheol-Young Park; Sung Woo Park
Journal:  J Diabetes Investig       Date:  2013-07-01       Impact factor: 4.232

9.  Macrophage Migration Inhibitory Factor and Malondialdehyde as Potential Predictors of Vascular Risk Complications in Type 2 Diabetes Mellitus: Cross-Sectional Case Control Study in Saudi Arabia.

Authors:  Heba Kamal Morsi; Manar Mohammad Ismail; Hassan Abdelaziz Hassan Gaber; Amani Abdelhamid Elbasmy
Journal:  Mediators Inflamm       Date:  2016-05-19       Impact factor: 4.711

Review 10.  The Wide and Complex Field of NAFLD Biomarker Research: Trends.

Authors:  Erika Wichro; Tanja Macheiner; Jasmin Schmid; Barbara Kavsek; Karine Sargsyan
Journal:  ISRN Hepatol       Date:  2014-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.